Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-32

Shareholders unfortunately will need to focus on the low hanging fruit deals (Wyon etc) and leave the big ones as a massive bonus.

Life science looks like it will get over the line before batteries.

It will be interesting to see how big Vidcare will actually be - The ongoing testing of AnteoBind NXT by Vidcare Innovations (Vidcare) is yielding promising results as
we work to evaluate and optimize it for a specific project-

"Given these encouraging results and the progress toward completing the evaluation, AnteoTech
anticipates finalising the program results and, contingent upon their continued success, entering into
a commercial supply agreement.
Further to this, Vidcare has expressed an interest in utilising the AnteoBind™ technology in other
products and making AnteoBind NXT a critical component of their growing product pipeline."

The only problem I see I notice timeline now seem to be lass than forthcoming from the company.

Cheers

M.oz